Tianjin Medical Journal

Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (5): 552-556.doi: 10.11958/20211591

Previous Articles     Next Articles

Research progress of APC-EPCR-PAR1 pathway in rheumatoid arthritis

LIU Xuanqi1, 2, LIU Huiyang1, 2, ZHAO Jingyang1, 3, YIN Fangrui1, 2, 3, BAI Li1, 2, 3, WANG Yongfu1, 2, 3△   

  1. 1 Department of Rheumatology and Immunology, the First Affiliated Hospital of Baotou Medical College (Institute of Rheumatology and Immunology, Baotou Medical College), Baotou 014000, China; 2 Baotou Medical College, Inner Mongolia University of Science and Technology; 3 Inner Mongolia Autoimmune Key Laboratory
  • Received:2021-07-08 Revised:2021-11-05 Published:2022-05-15 Online:2022-07-04

PDF (PC)

2546

Abstract: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease. Activated protein C (APC) is a natural anticoagulant transformed from its precursor protein C (PC), which plays a key role in the regulation of blood coagulation. APC can bind to endothelial protein C receptor (EPCR) and activate protein kinase receptor 1 (PAR1) on endothelial cells, thereby initiating cell protection and anti-inflammatory response. This article summarizes the research progress of each target on the APC-EPCR-PAR1 activation pathway in RA, discusses the potential therapeutic value of APC-EPCR-PAR1 pathway in RA diseases, and provides more options for the treatment of RA in the future.

Key words: arthritis, rheumatoid, protein C, receptors, cell surface, protein-tyrosine kinases, APC-EPCR-PAR1 pathway

CLC Number: